ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC

Press/Media: Press / Media

Period2018 Jun 3 → 2018 Jun 4

Media coverage

21

Media coverage